Ligand Pharmaceuticals Inc - Nov 1, 2022 Form 4 Insider Report for OmniAb Operations, Inc. (NONE)

Role: 10%+ Owner
Signature: /s/ Andrew Reardon, Chief Legal Officer and Secretary of Ligand Pharmaceuticals Incorporated
Stock symbol: NONE
Transactions as of: Nov 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 11/3/2022, 09:12 PM
Previous filing: Sep 30, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NONE	Common Stock	Other	$0	-16.9M	-100%	$0.00^*	0	Nov 1, 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Ligand Pharmaceuticals Inc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	In connection with the separation of the Issuer from the Reporting Person on November 1, 2022, the Reporting Person distributed all of the shares of Common Stock of the Issuer in the form of a dividend to its stockholders.